Autres langues Gilead Sciences, Inc. Deutsche Boerse AG

Actions

GIS

US3755581036

Produits pharmaceutiques

Temps réel estimé Tradegate 10:27:16 17/08/2026			Varia. 5j.	Varia. 1 janv.
118,71 ^EUR	-0,96%		+4,21%	+12,91%

11/08	Les géants mondiaux de la pharmacie investissent des milliards pour renforcer leur présence aux États-Unis	RE
11/08	Nucleai et Gilead Sciences font progresser l'intelligence tissulaire par IA grâce à une collaboration d'envergure sur les ADC en oncologie	CI

Autres langues

11/08	Global drugmakers invest billions to boost US presence
11/08	Nucleai And Gilead Sciences Advance AI-Powered Tissue Intelligence Through Large-Scale Oncology ADC Collaboration
07/08	Gilead Sciences : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
05/08	Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says
05/08	Gilead Sciences : Second Quarter 2026 Summary of Remarks
04/08	Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
04/08	Gilead Sciences Q2 Swings To Adjusted Loss, Revenue Rises
04/08	Gilead: Q2 Earnings Snapshot
04/08	(GILD) Gilead Sciences Expects Full Year 2026 Adjusted Loss Range of $0.30 - $0.65, vs. FactSet Est of $0.75 Loss
04/08	Earnings Flash (GILD) Gilead Sciences, Inc. Reports Q2 Revenue $7.80B, vs. FactSet Est of $7.40B
04/08	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26
04/08	Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q2 Adjusted Loss $6.75 per Share, vs. FactSet Est of $-7.26
04/08	CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
04/08	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on August 7, 2025.
04/08	Tranche Update on Gilead Sciences, Inc.'s Equity Buyback Plan announced on February 25, 2020.
04/08	Gilead second-quarter sales rise 8%, beating Wall Street estimates
04/08	Gilead Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Gilead Sciences, Inc. Declares Dividend for the Third Quarter of 2026, Payable on September 29, 2026
04/08	Gilead Sciences, Inc. Revises Earnings Guidance for the Full Year 2026
04/08	Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes
04/08	Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
04/08	Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
04/08	Morning Meeting: Wall Street entdeckt die "Magnificent Seven" wieder
04/08	Wall Street Reconnects with the Magnificent Seven
04/08	Pathos AI to license experimental breast cancer drug from China's Jiangsu Alphamab Biopharmaceutical